43 research outputs found
Ternary q-Virasoro-Witt Hom-Nambu-Lie algebras
In this paper we construct ternary -Virasoro-Witt algebras which
-deform the ternary Virasoro-Witt algebras constructed by Curtright, Fairlie
and Zachos using enveloping algebra techniques. The ternary
Virasoro-Witt algebras constructed by Curtright, Fairlie and Zachos depend on a
parameter and are not Nambu-Lie algebras for all but finitely many values of
this parameter. For the parameter values for which the ternary Virasoro-Witt
algebras are Nambu-Lie, the corresponding ternary -Virasoro-Witt algebras
constructed in this article are also Hom-Nambu-Lie because they are obtained
from the ternary Nambu-Lie algebras using the composition method. For other
parameter values this composition method does not yield Hom-Nambu Lie algebra
structure for -Virasoro-Witt algebras. We show however, using a different
construction, that the ternary Virasoro-Witt algebras of Curtright, Fairlie and
Zachos, as well as the general ternary -Virasoro-Witt algebras we construct,
carry a structure of ternary Hom-Nambu-Lie algebra for all values of the
involved parameters
Dendritic cells in cancer immunology and immunotherapy
Dendritic cells (DCs) are a diverse group of specialized antigen-presenting cells with key roles in the initiation and regulation of innate and adaptive immune responses. As such, there is currently much interest in modulating DC function to improve cancer immunotherapy. Many strategies have been developed to target DCs in cancer, such as the administration of antigens with immunomodulators that mobilize and activate endogenous DCs, as well as the generation of DC-based vaccines. A better understanding of the diversity and functions of DC subsets and of how these are shaped by the tumour microenvironment could lead to improved therapies for cancer. Here we will outline how different DC subsets influence immunity and tolerance in cancer settings and discuss the implications for both established cancer treatments and novel immunotherapy strategies.S.K.W. is supported by a European Molecular Biology Organization Long- Term Fellowship (grant ALTF 438– 2016) and a CNIC–International Postdoctoral Program Fellowship (grant 17230–2016). F.J.C. is the recipient of a PhD ‘La Caixa’ fellowship. Work in the D.S. laboratory is funded by the CNIC, by the European Research Council (ERC Consolidator Grant 2016 725091), by the European Commission (635122-PROCROP H2020), by the Ministerio de Ciencia, Innovación e Universidades (MCNU), Agencia Estatal de Investigación and Fondo Europeo de Desarrollo Regional (FEDER) (SAF2016-79040-R), by the Comunidad de Madrid (B2017/BMD-3733 Immunothercan- CM), by FIS- Instituto de Salud Carlos III, MCNU and FEDER (RD16/0015/0018-REEM), by Acteria Foundation, by Atresmedia (Constantes y Vitales prize) and by Fundació La Marató de TV3 (201723). The CNIC is supported by the Instituto de Salud Carlos III, the MCNU and the Pro CNIC Foundation, and is a Severo Ochoa Centre of Excellence (SEV-2015-0505).S